The ASPIRED syncope RCT, two studies in coronary artery calcium scoring, and the LEAP-Block trial of CSP vs RV pacing are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Syncope

• ASPIRED Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2605812
• REMOSYNCED Trial https://clinicaltrials.gov/study/NCT05066347

II TWO CAC Studies

• Atherosclerosis in Young Adults and Risk of Mortality Over 30 Years https://jamanetwork.com/journals/jamacardiology/fullarticle/2855732
• Predictive Utility of CAC Score Added to PREVENT Score https://jamanetwork.com/journals/jama/fullarticle/2853347

III Conduction System Pacing vs Standard RV Pacing for AV block

• LEAP-Block Trial https://jamanetwork.com/journals/jama/fullarticle/2855975
• Meta-analysis: CSP vs RV Pacing in Preserved or Mildly Reduced EF https://doi.org/10.1016/j.cjca.2026.04.009

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback on the nonobstructive HCM trials, AI-enhanced visits, timing of non-culprit PCI in STEMI, new tricuspid valve intervention, and EP at a crossroads are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Listener Feedback

Koelemen meta-analysis https://www.medrxiv.org/content/10.64898/2026.09.08.26362195v1.full.pdf

Improving SCD Risk Stratification in HCM https://pmc.ncbi.nlm.nih.gov/articles/PMC11026183/

II More on Nonobstructive HCM

Communication on Post-Hoc Analysis of ODYSSEY (mavacamten)

Mavacamten in Nonobstructive HCM 10.1016/j.jacc.2025.12.092

III Complete vs Staged PCI in STEMI With Multivessel Disease

Immediate vs Staged CR in Multivessel Disease and STEMI: Meta-Analysis https://doi.org/10.1016/j.jcin.2026.07.033

Timing of Nonculprit PCI for STEMI and Multivessel Disease: Editorial https://doi.org/10.1016/j.jcin.2026.08.009

COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775

FLOWER MI Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2104650

FRAME AMI Trial https://doi.org/10.1093/eurheartj/ehac763

iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918

COCUA Trial https://doi.org/10.1016/j.ahj.2023.01.020

MULTISTARS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307823

OPTION STEMI Trial 10.1016/S0140-6736(25)01529-6 External Link

CULPRIT SHOCK Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1710261

BioVasc Trial Substudy https://eurointervention.pcronline.com/article/immediate-versus-staged-complete-revascularisation-in-patients-presenting-with-stemi-and-multivessel-disease

Main BioVasc Trial 10.1016/S0140-6736(23)00351-3 External Link

FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149

IV A Call to Action for Electrophysiologists

Twenty Years at the Crossroads 10.1016/j.jacep.2026.09.023

EP at a Crossroads - Josephson 2007 https://doi.org/10.1016/j.hrthm.2006.12.045

EP at a Crossroads: A Revisit - Josephson 2016 https://doi.org/10.1016/j.hrthm.2016.07.024

V FDA Approves Another Tricuspid Valve Repair System

Press release https://www.edwards.com/newsroom/news/2026-10-21-fda-approval-of-edwards-lifesciences--pascal-preci

TRIC I HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2606934

CLASP II TR Trial https://pubmed.ncbi.nlm.nih.gov/42855029/

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Some promising studies in amyloidosis, aficamten in nonobstructive HCM, costs of the microaxial flow pump in cardiogenic shock, and more on the VESALIUS trial of evolocumab are the topics John Mandrola, MD, discusses in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I Light Chain Amyloidosis – A Potentially Helpful Drug

Anselamimab Does Not Reduce Light-Chain Amyloidosis Deaths

https://www.medscape.com/viewarticle/anselamimab-does-not-reduce-light-chain-amyloidosis-deaths-2026a1000z79

II Aficamten in Nonobstructive HCM: The ACACIA trial

III Microaxial Flow Pump Cost Analysis of Danger Shock

IV More on Evolocumab at ESC: Vesalius Trial Substudies

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

https://www.medscape.com/viewarticle/1003092

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.